<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40875502</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">25m15848</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.25m15848</ELocationID><Abstract><AbstractText><b>Objective:</b> Lumateperone, a mechanistically novel antipsychotic, simultaneously modulates serotonin, dopamine, and glutamate neurotransmission. This phase 3, randomized, double-blind, placebo-controlled trial investigated efficacy and safety of adjunctive lumateperone 42 mg in patients with major depressive disorder (MDD) with inadequate antidepressant therapy (ADT) response. <b>Methods:</b> From July 2021 to February 2024, eligible adult outpatients (18-65 years) had <i>DSM-5</i>-defined MDD with inadequate response to 1 or 2 ADTs in the current depressive episode and Montgomery-&#xc5;sberg Depression Rating Scale (MADRS) Total score &#x2265;24, Clinical Global Impression Scale-Severity (CGI-S) score &#x2265;4, and Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score &#x2265;14. Patients were randomized to 6-week oral adjunctive placebo (n=243) or adjunctive lumateperone 42 mg (n=242). Primary and key secondary end points were change from baseline to day 43 in MADRS Total and CGI-S scores. Safety was assessed. <b>Results:</b> Lumateperone + ADT met primary and key secondary end points, with significantly greater improvement at day 43 vs placebo + ADT in MADRS Total score (least squares mean difference [LSMD] vs placebo= -4.9; effect size [ES]= -0.61; <i>P</i> &lt; .0001) and CGI-S score (LSMD =-0.7; ES = -0.67; <i>P</i> &lt;.0001). Lumateperone + ADT significantly improved patient-reported depression vs placebo + ADT at day 43 (QIDS-SR-16 Total score, LSMD= -2.4; ES= -0.50; <i>P</i> &lt; .0001). Lumateperone + ADT was generally well tolerated. Treatment-emergent adverse events (&#x2265;5%, twice placebo) were dry mouth (placebo + ADT, 2.1%; lumateperone + ADT, 10.8%), fatigue (2.1%; 9.5%), and tremor (0.4%; 5.0%), with minimal risk for weight gain or cardiometabolic abnormalities. Emergence of suicidal ideation was low (placebo + ADT, 3.5%; lumateperone + ADT, 1.4%). <b>Conclusions:</b> Lumateperone 42 mg adjunctive to ADT significantly improved depression symptoms and disease severity vs adjunctive placebo and was generally well tolerated in patients with MDD with inadequate ADT response. <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT04985942.</AbstractText><CopyrightInformation>&#xa9; Copyright 2025 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durgam</LastName><ForeName>Suresh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Intra-Cellular Therapies, a Johnson &amp; Johnson Company, Bedminster, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Corresponding Author: Suresh Durgam, MD, Intra-Cellular Therapies, a Johnson &amp; Johnson Company, 135 US Highway 202/206, Ste 6, Bedminster, NJ 07921 (sdurgam@itci-inc.com).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earley</LastName><ForeName>Willie R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Intra-Cellular Therapies, a Johnson &amp; Johnson Company, Bedminster, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozauer</LastName><ForeName>Susan G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Intra-Cellular Therapies, a Johnson &amp; Johnson Company, Bedminster, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Changzheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intra-Cellular Therapies, a Johnson &amp; Johnson Company, Bedminster, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakkis</LastName><ForeName>Hassan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Intra-Cellular Therapies, a Johnson &amp; Johnson Company, Bedminster, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego and Riverside; La Jolla, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04985942</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>70BSQ12069</RegistryNumber><NameOfSubstance UI="C000705749">lumateperone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="Y">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006576" MajorTopicYN="N" AutoHM="Y">Heterocyclic Compounds, 4 or More Rings</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>20</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>20</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40875502</ArticleId><ArticleId IdType="doi">10.4088/JCP.25m15848</ArticleId><ArticleId IdType="pii">25m15848</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>